Adnan Adil HİŞMİOĞULLARI, Tünay KONTAŞ AŞKAR, Hatice Nur ER SARIKAYA, Olga BÜYÜKLEBLEBİCİ

Effect of vanadium (IV) chloride supplementation on appetite-related hormone levels in rats with experimentally induced diabetes

Vanadium is one of the essential trace elements for mammals, which has important functions in the metabolism of carbohydrates. There is limited data about the effects of vanadium (IV) chloride supplementation on appetite-related hormones in literature. Our target was to analyse the impacts of vanadium supplementation on appetite-related hormone (leptin, nesfatin-1 and apelin) levels in rats with experimentally induced diabetes. Twenty eight male Sprague–Dawley albino rats were used in this study. After formation of diabetes, 0.3 mg/mL of vanadium was added to drinking water of rats for four weeks. A substantial increment was found in serum glucose (p < 0.001), HbA1c (p < 0.001), HOMA-IR (p < 0.01), and leptin (p < 0.001) levels and a significant decrease in insulin, apelin and nesfatin-1 concentrations in diabetic rats. Moreover, blood glucose, HbA1c, HOMA-IR, and leptin levels decreased in diabetic + vanadium group, but nesfatin-1 (1.74 ± 0.94 ng/mL), apelin (1.74 ± 0.94 ng/mL), and insulin concentrations were found higher compared with the diabetic group. As a result of this study, vanadium has increased the levels of circulating nesfatin-1 and apelin levels in diabetic rats while decreasing blood glucose and leptin concentrations. But further studies are required to determine the blood glucose lowering effects of vanadium and its relationship with appetite related hormones in diabet.

PDF

___

1. Salsali A, Nathan W. A review of types 1 and 2 diabetes mellitus and their treatment with insulin. American Journal of Therapeutics 2006; 13: 349-361. doi: 10.1097/00045391- 200607000-00012
2. Yurt S, Erman H, Korkmaz GG, Kosar AF, Uysal P et al. The role of feed regulating peptides on weight loss in patients with pulmonary tuberculosis. Clinical Biochemistry 2013; 46: 40- 44.
3. Sandal S, Tekin S. Adipoz dokudan salgılanan bir hormon: apelin. İnönü Üniversitesi Sağlık Bilimleri Dergisi 2013; 1: 55-62.
4. Stengel A, Mori M, Taché Y. The role of nesfatin-1 in the regulation of food intake and body weight: recent developments and future endeavors. Obesity Reviews 2013; 14: 859-870. doi: 10.1111/obr.12063
5. Willsky GR, Chi LH, Kostyniak PJ, Smee JJ, Trujillo AM et al. Antidiabetic effects of a series of vanadium dipicolinate complexes in rats with streptozotocin-induced diabetes. Coord Chemical Reviews 2011; 255: 2258-2269. doi: 10.1016/j.ccr.2011.06.015
6. Bishayee A, Waghray A, Patel MA, Chatterjee M. Vanadium in the detection, prevention and treatment of cancer. Cancer Letters 2010; 294: 1-12. doi: 10.1016/j.canlet.2010.01.030
7. Fawcett P, Farquhar SJ, Walker RJ, Thou T, Lowe G et al. The effect of oral vanadyl sulfate on body composition and performance in weight-training athletes. International Journal of Sport Nutrition and Exercise Metabolism 1996; 6: 382-390. doi: 10.1123/ijsn.6.4.382
8. Godeny S, Borbely-Kiss I, Koltay E, Laszlo S, Szabo G. Determination of trace and bulk elements in plasma and erythrocytes of diabetic pregnant women by pixe method. International Journal of Clinical Obstetrics and Gynaecology 1986; 24: 201-207. doi: 10.1016/0020-7292(86)90098-6
9. Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlank R et al. Metabolic effects of vanadyl sulfate in humans with noninsulin-dependent diabetes mellitus: in vivo and in vitro studies. Metabolism 2000; 49: 400-410. doi: 10.1016/s0026- 0495(00)90418-9
10. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low- density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972; 18: 499-502.
11. Haffner SM, Greenberg AS, Weston W M, Chen H, Williams K et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684. doi: 10.1161/01.CIR.0000025403.20953.23
12. Ganong WF. Review of Medical Physiology. 17th ed. Norwalk, CT, USA: Appleton and Lange; 1995.
13. Itzhak G, Dov G, Eytan G, Mati F, Yoram S. Insulin-like effects of vanadium: basic and clinical implications. Journal of Inorganic Biochemistry 2000; 80: 21-25. doi: 10.1016/s0162- 0134(00)00035-0
14. Yao J, Battell ML, Mcneill JH. Acute and chronic response to vanadium following two methods of streptozotosin-diabetes induction. Canadian Journal of Physiology and Pharmacology 1997; 75: 83-90. doi: 10.1016/j.ccr.2011.06.015
15. Ramanadham S, Mongold JJ, Brownsey RW, Cros GH, McNeill JH. Oral vanadyl sulfate treatment of diabetes mellitus in rats. American Journal of Physiology 1989; 257: 904-911. doi: 10.1152/ajpheart.1989.257.3.H904
16. Cam MC, Rodrigues B, McNeill JH. Distinct glucose lowering and beta cell protective effects of vanadium and food restriction in streptozotocin-diabetes. European Journal of Endocrinology 1999; 141: 546-554. doi: 10.1530/eje.0.1410546
17. Shahi MM, Haidari F, Shiri MR. Comparison of effect of resveratrol and vanadium on diabetes related dyslipidemia and hyperglycemia in streptozotocin induced diabeticrats. Advanced Pharmaceutical Bulletin 2011; 1: 81-86. doi: 10.5681/apb.2011.012
18. Palumbo PJ. Metformin: effect on cardiovascular risk factor in patients with non- insulin dependent diabetes mellitus. Journal of Diabetes and its Complications 1998; 12: 110-119. doi: 10.1016/s1056-8727(97)00053-6
19. Arvind K, Pradeep R, Deepa R, Mohan V. Diabetes and coronary artery diseases. Indian Journal of Medical Research 2002; 116: 163-176.
20. Yashino G, Hirano T, Kazumi T. Dyslipidemia in diabetes mellitus. Diabetes Research Clinical Practice 1996; 33: 1-14. doi: 10.1016/0168-8227(96)01263-6
21. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nature Clinical Practice Endocrinology and Metabolism 2009; 5: 150-159. doi: 10.1038/ncpendmet1066
22. Adamu S, Ige AA, Jatau ID, Neils JS, Useh NM. Changes in the serum profiles of lipids and cholesterol in sheep experimental model of acute African trypanosomosis. African Journal of Biotechnology 2008; 7: 2090-2098. doi: 10.5897/AJB08.011
23. Battel ML, Yuen VG, McNeill JH. Treatment of BB rats with vanadyl sulfate. Pharmacy and Pharmacology Communications 1992; 1: 291-301.
24. Tunalı S,Yanardağ R. Effect of vanadyl sulfate on the status of lipid parameters and on stomach ond spleen tissues of streptozotocin-ınduced diabetic rats. Pharmacological Research 2006; 53: 271-277. doi: 10.1016/j.phrs.2005.12.004
25. Aşkar Ş, Aşkar TK, Güzel M. Austral Journal Of Veterinary Sciences 2018; 50:119-123.
26. Li Z, Gao L, Tang H, Yin Y, Xiang X et al. Peripheral effects of nesfatin-1 on glucose homeostasis. PLoS One 2013; 8: e71513. doi: 10.1371/journal. pone.0071513
27. Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regulatory Peptides 2010; 159: 72-77. doi: 10.1016/j.regpep.2009.11.003
28. Zhang Z, Li L, Yang M, Liu H, Boden G et al. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Experimental and Clinical Endocrinology and Diabetes 2012; 120: 91-95. doi: 10.1055/s-0031-1286339
29. Malmström R, Taskinen MR, Karonen SL, Jarvinen HY. Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM. Diabetologia 1996; 39: 993-996.
30. Wannamethee SG, Lowe GD, Rumley A, Cherry L et al. Adipokines and risk of type 2 diabetes in older men. Diabetes Care 2007; 30: 1200-1205.
31. Maahs DM, Hamman RF, D’Agostino RJ, Dolan LM. The association between adiponectin/ leptin ratio and diabetes type: the Search for Diabetes in Youth Study. The Journal of Pediatric Research 2009; 155: 133-135.
32. Tuominen JA, Ebeling P, Heiman ML, Stephens T, Koivisto VA. Leptin and thermogenesis in humans. Acta Physiologica Scandinavica 1997; 160: (1) 83-87.
33. Segal KR, Landt M, Klein, S. Relationship between insülin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996; 45: 988-991.
34. Kamoda T, Saitoh H, Nakahara S, Izumi I, Hirano et al. Serum leptin and insulin concentrations in prepubertal lean, obese and insulin-dependent diabetes mellitus children. Clinical Endocrinology 1998; 49: 385-389.
35. Aktaş G, Şit M, Tekçe H. Yeni adipokinler: Leptin, Adiponektin ve Omentin. Abant Tıp Dergisi 2013; 2 (1): 56-62.
36. Boucher J, Masri B, Daviaud D, Gesta S, Guigne C et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146 (4): 1764-1771.
37. Adamu S, Ige AA, Jatau ID, Neils JS, Useh NM. Changes in the serum profiles of lipids and cholesterol in sheep experimental model of acute African trypanosomosis. African Journal of Biotechnology 2008; 7: 2090-2098. doi: 10.5897/AJB08.011
38. Erdem G, Dogru T, Sonmez A, Tapan S. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Experimental Clinical Endocrinology and Diabetes, 2008; 116: 289-292.
39. Sorhede Winzell M, Magnusson C, Ahren B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regulatory Peptides 2005; 131: 12- 17. doi: 10.1016/j.regpep.2005.05.004.